Suppr超能文献

慢性自身免疫性血小板减少性紫癜中血小板膜糖蛋白IIIa上辅助性T细胞表位的定位

Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura.

作者信息

Sukati Hosea, Watson Henry G, Urbaniak Stanislaw J, Barker Robert N

机构信息

Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom.

出版信息

Blood. 2007 May 15;109(10):4528-38. doi: 10.1182/blood-2006-09-044388. Epub 2007 Feb 1.

Abstract

Chronic autoimmune thrombocytopenic purpura (AITP) is associated with autoantibodies specific for platelet membrane components, often including glycoprotein GPIIIa. T helper (Th) cells reactive with GPIIIa, which are capable of driving the autoantibody response, are activated in AITP, and the aim here was to map the epitopes that they recognize. Peripheral blood mononuclear cells (PBMCs) were obtained from 31 patients with AITP and 30 control donors and stimulated with a panel of 86 overlapping synthetic 15-mer peptides spanning the complete sequence of GPIIIa. One or more peptides elicited recall proliferation by PBMCs from 28 of the patients, and, typically, multiple sequences were stimulatory. In contrast, responses in healthy control donors were rare (chi-square test = 115.967; P <or= .001). It was confirmed that the proliferating PBMCs from patients were cells of the CD3(+)CD4(+) helper phenotype that were MHC class II restricted. Despite variation between different cases of AITP, particular sequences were commonly recognized with PBMCs from 24 patients (77%) responding to 1 or more of the 4 most dominant peptides. Mapping such dominant autoreactive helper epitopes is the first step in the development of new approaches to the treatment of AITP, based on the use of peptides to tolerize Th cells specific for platelet glycoproteins.

摘要

慢性自身免疫性血小板减少性紫癜(AITP)与针对血小板膜成分的自身抗体有关,这些成分通常包括糖蛋白GPIIIa。与GPIIIa反应的辅助性T(Th)细胞能够驱动自身抗体反应,在AITP中被激活,本文旨在绘制它们识别的表位。从31例AITP患者和30例对照供体中获取外周血单个核细胞(PBMC),并用一组86个重叠的合成15肽刺激,这些肽覆盖了GPIIIa的完整序列。一种或多种肽可引起28例患者的PBMC产生回忆增殖,通常多个序列具有刺激作用。相比之下,健康对照供体中的反应很少见(卡方检验=115.967;P≤0.001)。已证实患者增殖的PBMC是CD3(+)CD4(+)辅助表型的细胞,受MHC II类分子限制。尽管不同AITP病例之间存在差异,但特定序列通常被24例患者(77%)的PBMC识别,这些患者对4种最主要的肽中的1种或多种有反应。绘制此类主要的自身反应性辅助表位是开发AITP治疗新方法的第一步,该方法基于使用肽使针对血小板糖蛋白的Th细胞产生耐受。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验